COPD & Lung Disease stem cell therapy — your questions answered (2026)

About stem cell therapy for COPD & Lung Disease

Chronic obstructive pulmonary disease (COPD) is persistent airflow limitation associated with airway and lung-tissue damage, commonly from smoking or other exposures. MSC and exosome research explores inflammatory and repair pathways, but intravenous distribution, laboratory signalling or an imaging change does not establish restored alveoli, improved survival or prevention of exacerbations.

The evidence for COPD & Lung Disease

Human studies are heterogeneous and generally investigational. They should be assessed by exact product, dose, route, COPD phenotype and severity, comparator, lung function, exercise capacity, symptoms, exacerbations, hospitalisation and adverse events. The FDA consumer alert states that the promoted regenerative products it addresses have not been approved in the United States for pulmonary diseases including COPD. Do not stop inhaled medicines, oxygen or rehabilitation for an experimental offer.

Itemise respiratory assessment, product, administration, pulmonary rehabilitation, medicines, oxygen, travel, follow-up and management of infection, exacerbation or hospitalisation. A commercial infusion quote is not comparable with long-term evidence-based COPD care and must not divert resources from smoking cessation or established treatment.

Can stem cells help COPD?

Cell therapy for COPD & Lung Disease may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Is it inhaled or infused?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

Will I reduce oxygen use?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an COPD & Lung Disease programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for COPD & Lung Disease (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to COPD & Lung Disease overview · COPD & Lung Disease cost →